SCHEMBL2157246

SCHEMBL2157246

CCc1c(C(=O)C(N)=O)c2c(OC(C)=O)cccc2n1Cc1ccccc1

nearest known ligand 0.80

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 19/20 0.80
PLA2G1B P04054 6/20 0.76
PLA2G10 O15496 6/20 0.76
PLA2G2E Q9NZK7 6/20 0.76
PLA2G5 P39877 5/20 0.76
PLA2G2F Q9BZM2 4/20 0.76
PLA2G2D Q9UNK4 4/20 0.76
PLA2G6 O60733 1/20 0.76
PLA2G2C Q5R387 1/20 0.76
PLA2G12B Q9BX93 1/20 0.76
PLA2G12A Q9BZM1 1/20 0.76
PLA2G3 Q9NZ20 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7112890 0.99 PLA2G2A (0.79) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL2157074 0.91 PLA2G2A (0.77) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL7976593 0.91 PLA2G2A (0.66) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL5319862 0.90 PLA2G2A (0.77) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL7962736 0.89 PLA2G2A (1.00) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL2157506 0.87 PLA2G2A (0.80) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL7837809 0.87 PLA2G2A (0.77) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
Varespladib SCHEMBL29358982 0.86 PLA2G2A (1.00) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
Varespladib SCHEMBL26726 0.86 PLA2G2A (1.00) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL12023837 0.85 PLA2G2A (0.78) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1157704-A1 REMEDIES OR PREVENTIVES FOR ISCHEMIC REFLOW FAILURE SHIONOGI & CO., LTD. (JP) 2001-11-28 EP claimed
EP-1007056-A1 METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS ELI LILLY AND COMPANY (US) 2000-06-14 EP claimed
WO-1999016453-A1 METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS ELI LILLY AND COMPANY (US) 1999-04-08 WO claimed
CN-116585306-A PLA2 inhibitors for immediate treatment of hymenoptera toxicity and other conditions due to histamine release 奥菲瑞克斯股份有限公司 2023-08-15 CN disclosed
CN-109562098-B PLA2 inhibitors for immediate treatment of hymenoptera toxicity and other conditions due to histamine release 奥菲瑞克斯股份有限公司 2023-04-21 CN disclosed
EP-2341045-A1 [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor Eli Lilly and Company (US) 2011-07-06 EP disclosed
WO-2007110230-A2 SECRETED PROTEINS AS EARLY MARKERS AND DRUG TARGETS FOR AUTOIMMUNITY, TUMORIGENESIS AND INFECTIONS INSTITUT PASTEUR (FR) 2007-10-04 WO disclosed
EP-1840573-A1 Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections INSTITUT PASTEUR (FR) 2007-10-03 EP disclosed
EP-1073440-B1 sPLA 2 INHIBITOR ESTERS LILLY CO ELI (US) 2004-10-20 EP disclosed
EP-1181276-A1 MORPHOLINO-N-ETHYL ESTER DERIVATIVE OF AN INDOLE SPLA-2 INHIBITOR ELI LILLY AND COMPANY (US) 2002-02-27 EP disclosed
CN-1299277-A Pharmaceutical composition containing phospholipase inhibitor sodium [ 3- (2-amino-1, 2-dioxyethyl) -2-ethyl-1 (benzyl) -1H-indol-4-yl ] oxy ] acetate SHIONOGI & CO (JP) 2001-06-13 CN disclosed
EP-1007046-A4 METHOD FOR TREATMENT OF CHRONIC BRONCHITIS LILLY CO ELI (US) 2000-11-29 EP disclosed
WO-2000069818-A1 MORPHOLINO-N-ETHYL ESTER DERIVATIVE OF AN INDOLE sPLA2 INHIBITOR ELI LILLY AND COMPANY (US) 2000-11-23 WO disclosed
EP-1007046-A1 1H-INDOLE-3-GLYOXYLAMIDES FOR THE TREATMENT OF CHRONIC BRONCHITIS ELI LILLY AND COMPANY (US) 2000-06-14 EP disclosed
US-5919943-A INHIBITION OF SPLA2 ELI LILLY AND COMPANY (US) 1999-07-06 US disclosed
US-5919810-A SEPTIC SHOCK ELI LILLY AND COMPANY (US) 1999-07-06 US disclosed
WO-1998042343-A1 METHOD FOR TREATMENT OF CHRONIC BRONCHITIS ELI LILLY AND COMPANY (US) 1998-10-01 WO disclosed
US-5733923-A SECRETORY PANCREATIC PHOSPHOLIPASE A2 ELI LILLY AND COMPANY (US) 1998-03-31 US disclosed